VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALNY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALNYAlnylam Pharmaceuticals, Inc.
$143.82$19.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALNYCash Flow

Alnylam Pharmaceuticals, Inc. (ALNY) Cash Flow Statement

24Y historyFree accessUpdated daily

Free cash flow reached $271.2M in 2026Q3 at an 18.6% margin, yet operating cash flow covered only 0.16 times reported net income and working capital swings such as -$281.7M in 2026Q1 suggest cash generation remains uneven and milestone-dependent.

Income StatementBalance SheetCash FlowRatios

ALNY Cash Flow Statement

Annual statement

ALNY Cash Flow Statement

Alnylam Pharmaceuticals, Inc. (ALNY) cash flow statement — 24-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02
Cash from Operations650.37M524.08M-8.31M104.16M-541.27M-641.69M-614.96M-278.43M-562.62M-382.79M-307.7M-189.14M-165.64M-68.66M-115.61M-87.07M-84.34M-72.14M65.49M196.52M-24.63M-16.48M-19.57M-12.83M-1.28M
Operating CF Margin %-14.11%-0.37%5.7%-52.18%-76%-124.78%-126.7%-751.08%-425.73%-652.48%-460.23%-327.61%-145.56%-173.26%-105.21%-84.31%-71.76%68.1%386.11%-91.46%-288.4%-457.46%-7288.64%-
Operating CF Growth %386.25%6405.1%-107.98%119.24%15.65%-4.35%-120.87%50.51%-46.98%-24.4%-62.68%-14.19%-141.26%40.61%-32.78%-3.23%-16.9%-210.16%-66.67%897.88%-49.41%15.76%-52.56%-903.76%-
Net Income2.72B313.75M-278.16M-440.24M-1.13B-852.82M-858.28M-886.12M-761.5M-490.87M-410.11M-290.07M-360.39M-89.22M-106.01M-57.65M-43.52M-47.59M-26.25M-85.47M-34.61M-42.91M-32.65M-25.03M-4.14M
Depreciation & Amortization55.43M55.66M56.67M54.05M44.47M47.57M74.44M54.37M6.43M13.37M15.13M19.05M11.93M10.23M9.04M5.13M4.94M5.99M5.73M4.08M3.81M3.12M2.44M838K36K
Stock-Based Compensation307.53M348.24M272.08M221.68M230.65M165.72M139.87M174.84M157.75M92.82M75.53M45.78M33.06M20.7M12.36M16.8M19.34M20.17M18.03M14.47M8.3M04.11M00
Deferred Taxes-1.91B-2.2M-106.76M00-55.7M-54.04M-11.29M-3.56M1.89M-6.98M0-42.29M-2.69M-22.39M3.5M10.74M-5.16M-5.5M1.89M-7.92M0-4.11M00
Other Non-Cash Items-99.19M253.42M261.94M257.9M350.32M216.37M95.75M-12.61M-6.84M2.91M1.51M984K221.46M449K364K1.08M3.71M4.86M9.59M7.12M8.43M6.55M7.16M8.46M172K
Working Capital Changes-427.71M-444.78M-214.08M10.76M-35.55M-162.82M-12.7M402.38M45.1M-2.9M17.22M35.12M-29.4M-8.12M-8.96M-55.93M-79.56M-50.41M63.9M254.42M-2.65M16.76M3.48M2.91M2.65M
Change in Receivables-129.05M-359.96M-86.55M-87.94M-45.6M-101.8M-56.24M-24.24M15.24M-10.67M-15.04M31.64M-35.69M-4.14M1.36M12.65M00843K00243K-310K00
Change in Inventory-15.99M8.47M13.59M18.37M-34.14M-26.41M-35.43M-32.41M-22.64M0003.29M191K-1.81M0000000000
Change in Payables-193.31M75.07M91.09M80.84M191.77M88.24M117.38M36.61M15.48M-4.94M10.1M1.68M8.84M1.83M-1.74M-3.51M-3.18M9.9M-1.24M-264K2.09M0-615K00
Cash from Investing-737.9M436.33M-116.84M-336.35M169.35M-273.3M-435.52M-417.68M272.94M-290.36M142.59M-321.32M-548.81M-130.5M3.37M81.96M17.84M14.43M17.94M-277.43M-30.05M-40.42M-34.59M-3.24M-562K
Capital Expenditures-149.64M-58.7M-34.28M-62.21M-72.06M-76.37M-70.36M-140.16M-126.89M-104.21M-64.56M-12.95M-8.96M-4.01M-8.35M-1.29M-4.73M-4.95M-10.76M-7.79M-4.99M-1.95M-9.01M-3.12M-562K
CapEx % of Revenue2.98%1.58%1.52%3.4%6.95%9.05%14.28%63.78%169.39%115.9%136.89%31.51%17.72%8.49%12.51%1.56%4.73%4.92%11.19%15.3%18.51%34.06%210.52%1772.16%-
Acquisitions000000000000-25M00-81.96M-17.84M-10M-100K2.34M040.42M0-121K0
Investments-------------------------
Other Investing39.63M57.63M57.76M-4.44M-13.19M-4.36M-31.2M23M-14.82M120M-150M-1.47M00-162K81.96M17.84M6.15M0-839K0-40.42M000
Cash from Financing102.46M-305.19M294.16M172.13M425.75M1.25B994.98M823.18M65.47M1.12B177.83M616.18M736.47M200.93M93.41M738K3.66M3.51M3.15M58.63M166.63M52.62M50.98M23.71M17.32M
Debt Issued (Net)-55.75M-546.95M00254M500M200M-30M0-120M150M0000000-6.76M-2.38M1.74M194K5.34M-1.1M0
Equity Issued (Net)57.17M250.03M302.95M147.46M259.36M246.27M99.5M781.9M65.47M1.16B13.71M585.04M707.04M172.18M86.44M738K993K3.51M9.91M61.01M164.89M52.42M45.31M27.48M17.34M
Dividends Paid0000000000000000000000000
Share Repurchases00000000-3.47M-257K-596K-378K-15.99M-1.39M-359K0000000000
Other Financing101.05M-8.27M-8.79M24.67M-87.61M500.85M695.48M71.28M083.89M14.13M31.14M29.42M28.74M6.97M02.67M00000327K-2.67M-28K
Net Change in Cash-1.54M690.15M153.77M-53.67M46.4M323.11M-50.58M127M-224.2M451.74M12.72M105.72M22.01M1.76M-18.82M-4.37M-62.87M-54.32M86.64M-22.8M112.2M-4.51M-2.92M7.72M17.32M
Free Cash Flow500.73M465.38M-42.59M41.95M-613.33M-718.07M-685.32M-418.58M-689.5M-487M-372.26M-202.09M-174.6M-72.66M-123.96M-88.36M-89.07M-77.09M54.73M188.73M-29.62M-18.43M-28.58M-15.95M-1.84M
FCF Margin %9.99%12.53%-1.89%2.29%-59.12%-85.05%-139.05%-190.48%-920.47%-541.64%-789.37%-491.74%-345.33%-154.05%-185.77%-106.77%-89.04%-76.69%56.91%370.81%-109.97%-322.46%-667.98%-9060.8%-
FCF Growth %126.2%1192.73%-201.54%106.84%14.59%-4.78%-63.72%39.29%-41.58%-30.82%-84.2%-15.74%-140.29%41.38%-40.29%0.8%-15.54%-240.87%-71%737.26%-60.68%35.5%-79.19%-766.68%-
FCF per Share3.633.46-0.330.34-5.04-6.06-5.96-3.83-6.85-5.38-4.35-2.41-2.35-1.18-2.47-2.08-2.12-1.851.334.88-0.93-0.84-2.40-16.92-5.55
FCF Conversion (FCF/Net Income)0.18x1.67x0.03x-0.24x0.48x0.75x0.72x0.31x0.74x0.78x0.75x0.65x0.46x0.77x1.09x1.51x1.94x1.52x-2.49x-2.30x0.71x0.38x0.60x0.51x0.31x
Interest Paid250.77M067.58M0000172K775K2.43M1.1M00000001.5M000000
Taxes Paid17.45M014.36M00002.57M1.07M114K111K66K011K17K05.77M5.84M2.67M000000

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetStrained
Cash FlowImproving
Top Statement Risk

Milestone-dependent cash generation volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Conversion Remains Erratic

According to reported quarterly figures, ALNY's operating cash flow was $341.0M in 2026Q3 against net income of $2.2B, a ratio of just 0.16 that signals most of the headline earnings are not backed by operating cash.

The gap between net income and operating cash flow is the central issue in this dataset, as the 2026Q3 net income figure is far larger than the cash generated from operations and appears to reflect non-operating or tax-related items rather than core activity. Across the ten quarters, OCF/NI ratios swing between negative and above 1.0, which suggests that earnings quality is highly sensitive to timing of collaboration receipts and working capital movements. Investors should treat reported net income as a poor proxy for underlying cash earnings until the composition of the 2026Q3 gain is clarified.

Free Cash Flow Turns Positive Unevenly

Reported free cash flow reached $271.2M in 2026Q3 at an 18.6% margin, up sharply from negative FCF in 2025Q1 and 2024Q4, indicating a genuine but inconsistent turn toward self-funding.

Free cash flow has moved from deeply negative readings in early 2025 to several strong positive quarters, with 2025Q3 at $313.0M and 2026Q3 at $271.2M, which reflects the commercial ramp of the TTR franchise. However, quarterly FCF margins range from roughly -21% to 25%, so the trajectory is more a series of step changes than a steady compounding trend. The durability of these inflows depends on whether product-driven operating cash can carry the business without reliance on lumpy partner payments.

Working Capital Swings Drive Quarterly Noise

Working capital changes were -$103.2M in 2026Q3 and -$281.7M in 2026Q1 according to reported cash flow figures, large enough to materially distort quarterly operating cash flow.

The magnitude of working capital movements relative to operating cash flow indicates that receivable timing and collaboration-related balances are a meaningful driver of reported OCF. A large outflow in 2026Q1 followed by a partial reversal implies that cash conversion is sensitive to billing cycles rather than purely to demand. Analysts should monitor whether receivable and inventory balances normalize, since persistent build-ups would suggest weaker collection efficiency than headline revenue growth implies.

Capital Intensity Remains Light Relative to Revenue

Based on reported figures, CapEx ran at only 0.8% to 2.7% of revenue across recent quarters, with 2026Q2 at $34.7M, consistent with an asset-light, outsourced-manufacturing-heavy model.

Low capital intensity means that the bulk of cash generation is available for pipeline funding and debt service rather than plant maintenance. D&A broadly tracks CapEx at roughly $13M to $14M per quarter, suggesting that maintenance reinvestment is modest and that growth capex has not yet become a major claim on cash. This structure supports margin flexibility, though it also means the company relies on third parties for manufacturing capacity.

Stock Compensation Masks True Cash Burden

As reported in financial statements, stock-based compensation ran between $56.7M and $111.7M per quarter, a non-cash add-back that flatters operating cash flow relative to the economic cost of employee pay.

Because SBC is excluded from operating cash outflows, the reported OCF partially reflects a cost that is settled in equity rather than cash, which may overstate the cash economics available to shareholders. The recurring size of this charge suggests that management compensation is a material component of the cost base, and dilution from it may offset part of the apparent cash improvement. Investors should evaluate free cash flow after accounting for SBC when assessing true owner earnings.

ALNY — Frequently Asked Questions

Quick answers to the most common questions about buying ALNY stock.

How much cash does Alnylam Pharmaceuticals, Inc. (ALNY) generate from operations?

Alnylam Pharmaceuticals, Inc. (ALNY) generated $524.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Alnylam Pharmaceuticals, Inc.'s free cash flow?

Alnylam Pharmaceuticals, Inc. (ALNY) generated $465.4M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Alnylam Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Alnylam Pharmaceuticals, Inc. (ALNY) spent $58.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.